DUET-ADNCT06709014
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 71 versions: 49 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Final enrollment: 861 participants (planned 760)
- Notable Eligibility criteria expanded, about 40 words
- Primary endpoints: details revised at 2 of 2 entries
- Interventions: Placebo (Drug), buntanetap/posiphen (Drug) to Placebo (Drug), buntanetap/posiphen (Drug)
- Site details revised at 7 of 78 sites
- Minor Trial status changed: Recruiting → Active, Not Recruiting
- Trial sites reduced: 81 → 78 locations
- Minor Site details revised at 9 of 81 sitesv68
- Minor Site details revised at 8 of 81 sitesv67
Show 44 earlier versionsHide 44 earlier versions
- Minor Site details revised at 1 of 81 sitesv66
- Minor Study sites: 83 to 81v65
- Minor Site details revised at 1 of 83 sitesv64
- Minor Site details revised at 4 of 83 sitesv63
- Minor Site details revised at 4 of 83 sitesv62
- Minor Collaborators: 1 to 2v61
- Minor Site contacts updated at 1 of 83 sitesv60
- Notable Eligibility criteria revisedv59
- Minor Study sites: 84 to 83v57
- Minor Study sites revised (84)v56
- Minor Site contacts updated at 1 of 84 sitesv55
- Minor Site details revised at 6 of 84 sitesv54
- Minor Site details revised at 3 of 84 sitesv53
- Minor Site details revised at 1 of 84 sitesv52
- Minor Site details revised at 1 of 84 sitesv51
- Minor Study sites: 85 to 84v50
- Minor Site details revised at 2 of 85 sitesv49
- Minor Study sites: 86 to 85v48
- Minor Site details revised at 1 of 86 sitesv47
- Minor Site details revised at 1 of 86 sitesv46
- Minor Study sites: 85 to 86v45
- Minor Study sites: 81 to 85v44
- Notable Eligibility criteria expanded, about 27 words
- Secondary endpoints shortened, about 23 words
- Site details revised at 2 of 81 sites
- Minor Study sites: 79 to 81v42
- Minor Study sites: 78 to 79v41
- Minor Site details revised at 3 of 78 sitesv40
- Minor Study sites: 76 to 78v39
- Minor Study sites: 75 to 76v38
- Minor Study sites: 72 to 75v37
- Minor Site details revised at 2 of 72 sitesv36
- Minor Site details revised at 7 of 72 sitesv35
- Minor Study sites: 58 to 72v34
- Minor Study sites: 56 to 58v33
- Minor Study sites: 54 to 56v32
- Minor Study sites: 53 to 54v31
- Minor Study sites: 47 to 53v30
- Minor Site details revised at 1 of 47 sitesv29
- Minor Study sites: 45 to 47v28
- Minor Study sites: 42 to 45v27
- Minor Site details revised at 2 of 42 sitesv26
- Minor Study sites: 41 to 42v25
- Minor Study sites: 39 to 41v24
- Minor Study sites: 36 to 39v23
- Minor Study sites: 33 to 36v22
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Timeframe: From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Timeframe: From screening to 6-month readout, to end of treatment at 18 months.
Arms and interventions
buntanetapExperimental
PlaceboPlacebo comparator
Drugs: buntanetap/posiphen, Placebo
Sites
78 sites in 1 country